SCHEMBL20580588

SCHEMBL20580588

Cc1nc(Cl)cc(Nc2ncc(-c3ccncc3)s2)n1

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KIT P10721 14/20 0.60
FLT3 P36888 14/20 0.60
NTRK1 P04629 2/20 0.60
SRC P12931 2/20 0.60
KDR P35968 5/20 0.49
LIMK1 P53667 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22917459 0.89 KDR (0.62) KITFLT3SRCKDR
SCHEMBL29539891 0.89 KDR (0.62) KITFLT3SRCKDR
SCHEMBL5889064 0.87 KIT (0.62) KITFLT3NTRK1SRCKDR
SCHEMBL12078234 0.86 KDR (0.47) KITFLT3NTRK1SRCKDR
SCHEMBL29539419 0.80 KIT (0.57) KITFLT3NTRK1SRCKDR
SCHEMBL22917465 0.80 KIT (0.57) KITFLT3NTRK1SRCKDR
SCHEMBL20633811 0.80 CHRNA7 (0.46) KITFLT3NTRK1SRCKDR
SCHEMBL20633281 0.80 CHRNA7 (0.51) KITFLT3NTRK1SRCKDR
SCHEMBL22917493 0.79 KIT (0.80) KITFLT3NTRK1SRCKDR
SCHEMBL24292329 0.77 FLT3 (0.75) KITFLT3NTRK1SRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110831596-B Aminothiazole compounds as protein kinase inhibitors 台湾卫生研究院 2025-01-24 CN disclosed
EP-3638237-B1 AMINOTHIAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS NATIONAL HEALTH RES INST (TW) 2023-04-19 EP disclosed
US-20220288069-A1 INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. 2022-09-15 US disclosed
EP-3999064-A1 INHIBITORS OF TYROSINE KINASE Bridgene Biosciences, Inc. (US) 2022-05-25 EP disclosed
CN-114401722-A Inhibitors of tyrosine kinases 布里奇恩生物科学公司 2022-04-26 CN disclosed
US-11299489-B1 Thiazole compounds as protein kinase inhibitors NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2022-04-12 US disclosed
WO-2021016102-A1 INHIBITORS OF TYROSINE KINASE BRIDGENE BIOSCIENCES, INC. (US) 2021-01-28 WO disclosed
EP-3638237-A1 AMINOTHIAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS Shih, Chuan (US) 2020-04-22 EP disclosed
CN-110831596-A Aminothiazole compounds as protein kinase inhibitors 财团法人卫生研究院 2020-02-21 CN disclosed
US-10300061-B2 Aminothiazole compounds as protein kinase inhibitors NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2019-05-28 US disclosed
US-10300061-B2 Aminothiazole compounds as protein kinase inhibitors NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2019-05-28 US disclosed
WO-2018231910-A1 AMINOTHIAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2018-12-20 WO disclosed
US-20180353509-A1 AMINOTHIAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS NATIONAL HEALTH RES INST (TW) 2018-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220288069-A1 INHIBITORS OF TYROSINE KINASE ABL1, SRC, LCK KIT 688/4885FLT3 41/4885NTRK1 459/4885
US-20180353509-A1 AMINOTHIAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS ABL1, ERBB2, CSNK1E KIT 611/4885FLT3 207/4885NTRK1 784/4885
US-11299489-B1 Thiazole compounds as protein kinase inhibitors ABL1, RET, ERBB2 KIT 994/4885FLT3 94/4885NTRK1 760/4885
US-10300061-B2 Aminothiazole compounds as protein kinase inhibitors ABL1, ERBB2, CSNK1E KIT 611/4885FLT3 207/4885NTRK1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.